Renal News: Breaking Renal News, Comments and Articles.

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with type 2 diabetes with either a history of establis...

The glomerular basement membrane as a barrier to albumin

The glomerular basement membrane (GBM) is the central layer of the glomerular filtration barrier and is situated between endothelial cells and podocyte foot processes. The functional importance of the GBM versus that of podocytes and endothelial cell...

Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism

In this Review, the author discusses new insights into the pathogenesis of chronic kidney disease and describes a novel mechanism of ageing, both in the context of the fibroblast growth factor (FGF)–Klotho endocrine axis. In addition, the author pr...

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

Over the past 20 years, it has become clear that aldosterone exerts direct effects on the vasculature, heart and kidney beyond its effects on electrolyte handling in the distal tubule. In addition, mineralocorticoid-receptor activation has been shown...

Chronic kidney disease: Being overweight in early life linked with increased CKD risk

Acute kidney injury: Oral fluoroquinolone use and acute kidney injury

Transplantation: The impact of donor CMV infection on kidney graft outcome

Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments

Yale University researchers this week released the findings of two independent studies of Medtronic’s Infuse bone graft products. Parker Waichman, which offers free legal consultations for victims of Medtronic Infuse Bone Graft Injuries, notes that the results indicate that Infuse allegedly can cause cancer and male infertility, and that early published data was skewed toward the positive. New Y...

Renal sympathetic denervation: applications in hypertension and beyond

Increased sympathetic activity is associated with a number of diseases, including resistant hypertension. Renal denervation is becoming increasingly prevalent throughout Europe as a treatment for this condition. The pathophysiology of this technique,...

Markers of systemic inflammation predict survival in patients with advanced renal cell cancer

Alport Syndrome Foundation, Kidney Foundation of Canada Announce New Research Awards

PHOENIX—The Alport Syndrome Foundation (ASF) and The Kidney Foundation of Canada (KFOC)/Macquarie Research Fund are pleased to announce that they have awarded nearly $200,000 in joint funding for two Alport Syndrome research projects in 2013-2014.

AAKP, RPA Bring Kidney Disease Awareness to Capitol

TAMPA, Fla.—The American Association of Kidney Patients (AAKP) partnered with the Renal Physicians Association (RPA) to bring important health care issues to members of congress. The event took place June 10 in Washington, DC. This was the third successful joint Hill Day event between the two organizations. The goal of the congressional visits was

AKF Hosts Upcoming Event to Fight Kidney Disease

ROCKVILLE, Md.—Join the American Kidney Fund (AKF) this Saturday, June 22, from 9 a.m. to 2 p.m. for the free annual Kidney Action Day and raise kidney disease awareness.

PreDiabetes Centers Introduces Animated Film About Diabetes Risks and Symptoms

New Prediabetes Treatment Cartoon Warns People About Diabetes Danger Austin, TX (PRWEB) June 18, 2013 PreDiabetes Centers is excited to announce the release of a new animated diabetes health film in efforts to make people more aware of the dangers of type 2 diabetes, a serious health condition that affects how the body uses blood glucose, which can cause dangerous long-term health disorders. Tit...

Sigma-Tau Group : A New Efficient and Cost Effective Dialysis for Patients with End Stage Renal Disease

Thule Therapeutics S.A., an R&D Company of the Sigma-Tau Group, and Corequest Sagl announce extremely valuable findings on the use of L-Carnitine in peritoneal dialysis solutions opening up new opportunities in the treatment of end stage renal disease (ESRD). The prestigious American Journal of Kidney Disease recently published an article enti...

Natura Pet Issues Voluntary Recall of Specialized Dry Pet Foods Due to Possible Health Risk

Contact:  Natura Pet Consumer Relations – 800-224-6123       Natura Pet Products is voluntarily recalling specific lots of dry pet food because it has the potential to be contaminated with Salmonella. Salmonella can affect animals eating the products and there is risk to humans from handling contaminated pet products, especially if t...

Astellas and CiRA, Kyoto University discover efficient methods of differentiating nephron progenitor cells from human iPS/ES cells - Presented at ISSCR's 11th Annual Meeting -

  Tokyo, June 18, 2013 - Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) and Kyoto University’s Center for iPS Cell Research and Application (Director: Dr. Shinya Yamanaka; “CiRA”), as a part of their collaborati...

Use of 5{alpha}-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study

Objective To assess the association between 5α-reductase inhibitor (5-ARI) use in men with lower urinary tract symptoms and prostate cancer risk.Design Nationwide, population based case-control study...

Is "nitrofurantoin lung"on the increase?

Gupta and Trautner suggest using nitrofurantoin as prophylaxis for recurrent urinary tract infections (UTIs) in non-pregnant women.1 They mention the risk of pulmonary toxicity (“nitrofurantoin...

Don't forget the embalming fluid for treating recurrent infections . . .

In their review of recurrent urinary tract infections, Gupta and Trautner omit an important weapon in the antimicrobial arsenal, lowly hexamine (methenamine hippurate).1 With the increasing...

MPR Sports a Bold New Look

NEW YORK, June 18, 2013 /PRNewswire/ --MPR is excited to unveil a new logo and print design with its June 2013 edition. It's all part of an ongoing effort to freshen the look and feel of the publication, trusted by healthcare practitioners for over 28 years. (Photo: http://photos.prnewswire.com/prnh/20130618/NY33937 ) Through a continuous evolution MPR has expanded upon its foundation as a conc...

New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors

IRVINE, Calif., June 18, 2013 /PRNewswire-USNewswire/ -- Women are frequently the healthcare advocate for their loved ones or families, but unfortunately they often do not give the same priority to their own health. One in five women have kept information from their doctor because they were too embarrassed or too nervous to speak about it, according to a recent survey conducted by Allergan an...

Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting

RARITAN, N.J., June 18, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that 17 presentations on INVOKANA™ (canagliflozin) ― including Phase 3 clinical safety and efficacy data, and a health economic analysis ― will be made at the American Diabetes Association (ADA) 73rd Annual Scientific Sessions, June 21-25, in Chicago, Ill. INVOKAN...

Pentec Health Announces Issuance of Hong Kong Patent for Renal Nutritional Supplement PROPLETE®

Patent expands company's global reach. Philadelphia, PA (PRWEB) June 18, 2013 Pentec Health today announced that it has received a Hong Kong patent for PROPLETE®, its proprietary Intradialytic Parenteral Nutrition (IDPN) supplement for patients suffering from Chronic Kidney Disease. The issuance of this patent expands the company’s international presence, aligning with its strategy for...

Rockwell Medical Receives $20 Million in New Financing

WIXOM, MI -- (Marketwired) -- 06/18/13 -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it closed a $20 million debt financing with Hercules Technol...